PAHO, Argentina, Pfizer and Sinergium promote local production of the 20-valent pneumococcal vaccine for all of Latin America and the Caribbean

Buenos Aires, January 15, 2025 (PAHO) – The Pan American Health Organization (PAHO), the Government of Argentina, the Pfizer laboratory and the pharmaceutical company Sinergium Biotech announced a joint effort that will facilitate local production and regional access to the 20-valent pneumococcal conjugate vaccine (PCV20). This vaccine will help reduce the burden of pneumococcal diseases, offering improved protection for vulnerable populations, including children and older adults.

“PAHO is committed to increasing regional production of sustainable and innovative technologies, strengthening existing capacities and our regional purchasing mechanism, the Revolving Fund for Access to Vaccines,” said PAHO Director Jarbas Barbosa. “This collaboration reflects our commitment to ensuring equitable access to safe and effective vaccines that prevent serious diseases and save lives,” he added.

Through this initiative, not only Argentina will be a beneficiary of the local production of Sinergium Biotech, but also the rest of the countries in the region will be able to access doses of the vaccine through the PAHO Regional Revolving Funds, allowing be introduced more quickly and at competitive prices.

The countries of the region will be able to access it at competitive prices through the PAHO Regional Revolving Funds

The PCV10 and PCV13 vaccines have had a positive impact on the health of children in Latin America and the Caribbean. Estimates of the 2016 global burden of lower respiratory tract infections revealed that after the introduction of these vaccines, cases of invasive pneumococcal disease (IPD) caused by the serotypes covered in these vaccines in children under 5 years of age were significantly reduced. However, an increase was observed in other serotypes not covered by those vaccines.

PCV20, which includes seven additional serotypes compared to PCV13, promises to further strengthen protection against serious diseases caused by the bacteria Streptococcus pneumoniae or pneumococcus, responsible for pneumonia, meningitis and other serious infections, including those serotypes associated with antibiotic resistance. .

Pneumococcus remains a global public health problem. According to estimates by the Institute of Health Metrics and Evaluations (IHME), in 2021, 155,000 children under 5 years of age died worldwide due to pneumonia and meningitis caused by pneumococcus, of which 3,345 occurred in Latin America and the Caribbean. That same year, pneumococcal disease caused around 243,000 deaths in adults aged 70 years or older, of which around 18,000 were in Latin America and the Caribbean.

The PCV20 vaccine will be available for Latin America and the Caribbean from the beginning of 2025, with the estimate that the first doses produced in Argentina will be available in 2026. Thus, this vaccine, which is recommended for children under 2 years of age and adults over 60 and which is already being introduced in high-income countries, will also be available for countries in the region.

For more than 40 years, the PAHO Revolving Fund for Access to Vaccines has consolidated the demand of the countries of the region to make joint purchases, which gives them negotiating power and guarantees a uniform price under competitive conditions, regardless of the demand of each country. In the case of PCV20, countries will also be able to purchase it at a favorable price. Plus, shipping will be done regionally, reducing costs and carbon footprint. Another benefit of this vaccine, unlike PCV13, is that it will come in a prefilled syringe, making the administration process easier.

This effort, by helping to develop an ecosystem ready for the production and distribution of vaccines on a larger scale, also seeks to increase the region’s resilience to future pandemics and outbreaks, one of the lessons learned from the COVID-19 pandemic.

To see published note click here.

facebook
instagram
linkedin
twitter

Recent posts

Back    |   See all